12-132687321-C-T
Position:
Variant summary
Our verdict is Likely benign. Variant got -5 ACMG points: 0P and 5B. BP4_StrongBP6
The NM_006231.4(POLE):c.-6G>A variant causes a 5 prime UTR change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000627 in 1,499,624 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.00024 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000043 ( 0 hom. )
Consequence
POLE
NM_006231.4 5_prime_UTR
NM_006231.4 5_prime_UTR
Scores
2
Clinical Significance
Conservation
PhyloP100: -2.12
Genes affected
POLE (HGNC:9177): (DNA polymerase epsilon, catalytic subunit) This gene encodes the catalytic subunit of DNA polymerase epsilon. The enzyme is involved in DNA repair and chromosomal DNA replication. Mutations in this gene have been associated with colorectal cancer 12 and facial dysmorphism, immunodeficiency, livedo, and short stature. [provided by RefSeq, Sep 2013]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -5 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.87).
BP6
Variant 12-132687321-C-T is Benign according to our data. Variant chr12-132687321-C-T is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 246298.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=2, Uncertain_significance=2}.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
POLE | NM_006231.4 | c.-6G>A | 5_prime_UTR_variant | 1/49 | ENST00000320574.10 | NP_006222.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
POLE | ENST00000320574.10 | c.-6G>A | 5_prime_UTR_variant | 1/49 | 1 | NM_006231.4 | ENSP00000322570.5 |
Frequencies
GnomAD3 genomes AF: 0.000224 AC: 34AN: 151890Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
34
AN:
151890
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000185 AC: 2AN: 108316Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 60074
GnomAD3 exomes
AF:
AC:
2
AN:
108316
Hom.:
AF XY:
AC XY:
0
AN XY:
60074
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000430 AC: 58AN: 1347628Hom.: 0 Cov.: 32 AF XY: 0.0000421 AC XY: 28AN XY: 665022
GnomAD4 exome
AF:
AC:
58
AN:
1347628
Hom.:
Cov.:
32
AF XY:
AC XY:
28
AN XY:
665022
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000237 AC: 36AN: 151996Hom.: 0 Cov.: 33 AF XY: 0.000323 AC XY: 24AN XY: 74310
GnomAD4 genome
AF:
AC:
36
AN:
151996
Hom.:
Cov.:
33
AF XY:
AC XY:
24
AN XY:
74310
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
Asia WGS
AF:
AC:
2
AN:
3468
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:3Benign:2
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not provided Uncertain:1Benign:1
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jun 01, 2024 | POLE: BP4 - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Aug 30, 2018 | This variant is denoted POLE c.-6G>A, and describes a nucleotide substitution 6 base pairs upstream of the POLE start codon. This variant has not, to our knowledge, been published in the literature as pathogenic or benign. POLE c.-6G>A occurs in the Kozak sequence, the conserved nucleotides just upstream of the ATG start codon, and therefore may impact protein translation. POLE c.-6G>A was observed at an allele frequency of 0.069% (8/11474 alleles) in individuals of African ancestry in large population cohorts (Lek 2016). Based on the currently available information, it is unclear whether POLE c.-6G>A is a pathogenic or a benign variant. We consider it to be a variant of uncertain significance. - |
Colorectal cancer, susceptibility to, 12 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Mendelics | May 28, 2019 | - - |
POLE-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jan 09, 2024 | The POLE c.-6G>A variant is located in the 5' untranslated region. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.069% of alleles in individuals of African descent in gnomAD and has conflicting interpretations of pathogenicity including likely benign and uncertain (https://www.ncbi.nlm.nih.gov/clinvar/variation/246298/). Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
not specified Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Jul 06, 2017 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
RBP_binding_hub_radar
RBP_regulation_power_radar
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at